ANAVEX LIFE SCIENCES CORP.

For the period ended Sep 30, 2025. Filed Nov 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Nov 25, 2025

AVXL$1.22+6.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

ITEM 16. FORM 10-K SUMMARY

Not Applicable.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 25, 2025	ANAVEX LIFE SCIENCES CORP.
	By:	/s/ Christopher Missling, PhD
	Name:	Christopher Missling, PhD
	Title:	Chief Executive Officer (Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signatures	Title(s)	Date
/s/ Christopher Missling, PhD		November 25, 2025
Christopher Missling, PhD	Chief Executive Officer (Principal Executive Officer) and Director
/s/ Sandra Boenisch		November 25, 2025
Sandra Boenisch, CPA, CGA	Principal Financial Officer and Treasurer (Principal Accounting Officer)
/s/ Jiong Ma, PhD		November 25, 2025
Jiong Ma, PhD	Director, Chair
/s/ Claus van der Velden, PhD		November 25, 2025
Claus van der Velden, PhD	Director
/s/Athanasios Skarpelos		November 25, 2025
Athanasios Skarpelos	Director
/s/ Steffen Thomas, PhD		November 25, 2025
Steffen Thomas, PhD	Director
/s/ Peter Donhauser, D.O.		November 25, 2025
Peter Donhauser, D.O.	Director

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.